Capping drug prices will cripple innovation and harm public health

The Washington Examiner cited CEI’s expert on life-saving drugs and technology

The Competitive Enterprise Institute was similarly scathing. “As with many industries, the United States is on the frontier of innovation in the development of life-saving drugs and technology,” Jeremy Nighohossian of CEI wrote. “A Most Favored Nation approach will import the judgments of the foreign analysts who employ the lowest possible evaluations for those drugs.” 

What’s more, Nighohossian contended, “many of these nations face drug shortages due in part to pricing their drugs below market prices, and should the United States choose the lowest price among these nations, it will risk experiencing the worst shortages among these nations as well.”

Read more at the Washington Examiner